“Her deep expertise in pancreatic cancer and immunotherapy aligns perfectly with our mission, particularly as we advance our CAN-2409 program in borderline resectable pancreatic cancer following ...

NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal ...

Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and ...

for patients with locally advanced or borderline resectable pancreatic cancer in 4Q2024 and investigators recommended that the encouraging oncologic outcomes coupled with a favorable safety ...

In the Company’s randomized phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic cancer, positive survival data showed notable improvement in estimated median overall survival ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech ...

placebo-controlled phase 3 clinical trial of CAN-2409 in localized prostate cancer. In the Company’s randomized phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic ductal ...